Pharmaceutical Grade Nutritionals
The Food and Drug Administration requires that dietary supplement manufacturers follow Good Manufacturing Practices (GMP) for dietary supplements (21 CFR, part 111). USANA, however, voluntarily follows the more stringent GMP for pharmaceuticals as the basis for its quality assurance program, which regulates virtually every aspect of manufacturing, including facility design and maintenance, raw material specification and control, supplier validation, product design and testing, and more. This voluntary adherence to GMP for pharmaceuticals means that USANA treats nutritional supplements with the same care that goes into the manufacturing of over-the-counter products.
In addition to our own high standards of manufacturing, a variety of government agencies conduct periodic inspections of our facilities, requiring strict control of procedures and documentation. Our Salt Lake City, Utah, facility is certified to be in compliance with Good Manufacturing Practices (GMP) requirements set forth in NSF/ANSI Standard 173-2012, Dietary Supplements by NSF International, and it also became a registered U.S. Food and Drug Administration (FDA) Drug Establishment in 2011.
As such, all components of the manufacturing process are evaluated and inspected by the same FDA standards as are used for pharmaceutical products.
Additionally, in several countries around the world, supplements are more highly regulated than in the United States. In Australia, for example, the Therapeutic Goods Administration (TGA) mandates that manufacturers follow a set of GMP identical to pharmaceutical GMP in the United States. As an Australian supplier, USANA is regularly inspected and audited by the TGA to ensure that their GMP standards are met.
It is USANA’s mission to develop and provide the highest-quality, science-based products. By rigorously testing each product for potency and purity and by following pharmaceutical GMP, USANA sets the standard for excellence in dietary supplement manufacturing.
Last modified: August 2, 2024
